We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High Aldolase Levels Indicate Muscle or Liver Damage

By LabMedica International staff writers
Posted on 30 Oct 2009
A new aldolase assay is aimed at diagnosing patients who have muscle or liver damage.

Aldolase is an enzyme that helps convert glucose into energy and is found throughout the body but is primarily found in high levels in muscle tissue. More...
Elevated levels in the bloodstream can indicate a patient that has muscle or liver damage.

When the muscles are diseased or damaged, such as in muscular dystrophy, the cells deteriorate and break open causing the contents of the cells, including aldolase, to spill into the bloodstream. Aldolase is also found in the liver and cardiac muscle of the heart. Damage or disease to these organs, such as chronic hepatitis or a heart attack, will also increase aldolase levels in the blood.

Measuring the amount of aldolase in the blood indicates the degree of muscle damage. The Randox (Crumlin, UK) aldolase test is for the quantitative determination in serum or plasma and can be run manually or on the Randox RX series or on other automatic and semi-automatic analyzers.

Randox develops, manufactures, and markets clinical diagnostic products worldwide. Core products include: biochip array technology; clinical chemistry analyzers and reagents; and quality controls; recombinant proteins and antibodies.

Related Links:

Randox



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.